Generative AI software leader in clinical trial analytics, NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF) announced in a press release today that it will present new data demonstrating the potential of its proprietary NetraAI clinical trial solution to generate novel insights into key drivers of Parkinson’s disease.
NetraMark focuses on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry, using a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. By using a variety of ML methods, depending on the character and size of the data, the firm transforms the data into powerfully intelligent data that activates traditional AI/ML methods, resulting in the ability to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
In morning trade, U.S. shares were flat, and Canadian-listed shares were trading down.
Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
]]>